COVID-19 vaccines are coming – how will we know they work and are safe?
The results of the Pfizer vaccine trial are highly promising. But the road to eradicating the coronavirus is likely to be long and difficult
90% efficacy for Pfizer’s COVID-19 mRNA vaccine is striking. But we need to wait for the full data
Important questions remain: It’s unclear how long protection will last and if the vaccine protects against severe disease
The world needs pharmaceuticals from China and India to beat COVID-19
Chinese manufacturers make around 40% of all APIs used worldwide; China, India are the source of 75-80% of APIs imported to US
Can activism check Big Pharma’s profit motives?
As prices of life-saving drugs skyrocket, people from diverse fields are getting together to fight Big Pharma
Standing up to the US
India does not have to be apologetic about its patents law, which is fully compliant with WTO requirements on intellectual property protection
Cost of vaccination has risen 68 times in a decade, says report
Crisis looms as donor withdraws support to African countries; MSF urges GSK, Pfizer to slash vaccine price
Make unethical drug trials a punishable offence, say experts
Current laws do not fix penalty if such practices are found
Drug trials: Irked NHRC issues notices to Centre and Andhra Pradesh government
Says respond else face action
US piles on the pressure
Patent law, domestic content rules in solar and ICT policy come under attack
Big pharma’s dirty tricks
Drug giants from GSK, Abbott and Pfizer to Bayer have been fined for serious malpractices. They should be under close watch in India
Strong medicine for weak drug patents
Revocation of Pfizer, Roche patents for lacking inventive step signals healthy trend
The natco-pfizer test
Natco’s demand for a voluntary licence from Pfizer will establish how well the compulsory licence process works in India
Drug affordability test
Natco’s bid for a compulsory licence to manufacture a Bayer anti-cancer drug is a test of the law’s ‘reasonable price’ …